Holen Sie sich die Stockscreener-App
2.12
0.00%
0.00
Handel nachbörslich:
2.12
Schlusskurs vom Vortag:
$2.12
Offen:
$2.12
24-Stunden-Volumen:
99,980
Relative Volume:
0.38
Marktkapitalisierung:
$91.77M
Einnahmen:
$19.94M
Nettoeinkommen (Verlust:
$-37.37M
KGV:
-1.6693
EPS:
-1.27
Netto-Cashflow:
$-33.38M
1W Leistung:
+0.95%
1M Leistung:
-1.85%
6M Leistung:
-67.28%
1J Leistung:
-0.93%
1-Tages-Spanne:
$2.06
$2.17
1-Wochen-Bereich:
$1.90
$2.24
52-Wochen-Spanne:
$1.5735
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Rubric Capital Management LP Has $3.26 Million Stock Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Trading Down 3.6% - MarketBeat
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Are Smart Investors Making the Right Decision? Werewolf Therapeutics Inc (HOWL) - SETE News
Market Recap Check: Werewolf Therapeutics Inc (HOWL)’s Negative Finish at 2.16, Up/Down -2.70 - The Dwinnex
What is the investor’s view on Werewolf Therapeutics Inc (HOWL)? - US Post News
Analysts Offer Predictions for Werewolf Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:HOWL) - MarketBeat
Analysts Issue Forecasts for Werewolf Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:HOWL) - MarketBeat
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Forecasted to Post Q3 2024 Earnings of ($0.45) Per Share - MarketBeat
Brokers Issue Forecasts for Werewolf Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:HOWL) - Defense World
Vanguard Group Inc. Boosts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
1,688,054 Shares in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Bought by Janus Henderson Group PLC - MarketBeat
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly? - Simply Wall St
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 55.1% - Defense World
Hamilton Thorne Ltd. (OTCMKTS:HTLZF) Short Interest Update - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 55.1% in July - MarketBeat
Acadian Asset Management LLC Boosts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Inc (HOWL) Stock: A Year of Market Fluctuations - The InvestChronicle
WEREWOLF THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
RSI Oversold: 2 Stocks (HOWL, WKHS) Potentially Signaling a Contrarian Buy - Nasdaq
CFRA maintains sell on Rivian, price target at $8 By Investing.com - Investing.com India
H.C. Wainwright: Werewolf Therapeutics stock weakness 'misplaced'; reiterates buy - Investing.com
Werewolf Therapeutics (NASDAQ:HOWL) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright: Werewolf Therapeutics stock weakness 'misplaced'; reiterates buy By Investing.com - Investing.com UK
Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright - Defense World
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1 (HOWL) - Seeking Alpha
Financial Fitness Check: Examining Werewolf Therapeutics Inc (HOWL)'s Key Ratios – DWinneX - The Dwinnex
Werewolf Therapeutics Inc (HOWL) can make a big difference with a little luck – Sete News - SETE News
A stock that deserves closer examination: Werewolf Therapeutics Inc (HOWL) – US Post News - US Post News
Werewolf Therapeutics (NASDAQ:HOWL) Receives Buy Rating from HC Wainwright - Defense World
Werewolf Therapeutics (NASDAQ:HOWL) Receives “Market Outperform” Rating from JMP Securities - Defense World
Werewolf Therapeutics shares hold Buy rating By Investing.com - Investing.com Australia
Werewolf Therapeutics' (HOWL) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Flutter Entertainment announces total voting rights By Investing.com - Investing.com
Citi starts United Rentals shares coverage with buy rating, cites solid outlook By Investing.com - Investing.com South Africa
Werewolf Therapeutics shares hold Buy rating By Investing.com - Investing.com UK
Where Werewolf Therapeutics Stands With Analysts - Benzinga
Werewolf Therapeutics stock target held by BofA on early data - Investing.com
Werewolf Therapeutics Inc's Market Journey: Closing Weak at 2.34, Down -10.34 – DWinneX - The Dwinnex
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes - TipRanks
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating ... - GlobeNewswire
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - ForexTV.com
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - Yahoo Finance
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewswire
Closing Bell Recap: Werewolf Therapeutics Inc (HOWL) Ends at 2.89, Reflecting a -7.67 Downturn – DWinneX - The Dwinnex
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 26.1% in May - MarketBeat
SmartKem Executives Receive Stock Options and Cash Bonuses By Investing.com - Investing.com
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):